Project Grant R03DA064869
Award Date 9/1/26
Completion Date 8/31/28
Dollars Obligated $220K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Webster Groves, MO 63119, USA
Similar Awards
- The National Institute on Drug Abuse awarded New York University $411,187 on September 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct basic research on trial-to-trial variability in neural circuits and its impact on neural computation and behavioral accuracy. The project integrates theoretical models, statistical methods, and experimental datasets to characterize noise in neural circuits using rodent navigation and nonhuman primate decision-making tasks. The...
- The National Institute on Drug Abuse awarded the University of North Carolina at Chapel Hill $427,625 on July 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to support mapping neural circuit and network contributions to addiction development. The project introduces a novel MRI-compatible cocaine self-administration system integrating calcium imaging with fMRI (termed SORDINO-fMRI) to enable simultaneous recording of neuronal activity in the medial prefrontal cortex and...
- The National Institute on Drug Abuse awarded Carnegie Mellon University $217,672 on August 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to measure how addiction-associated genetic variants regulate gene expression across specific brain regions in response to opioids and cocaine. The research measures regulatory activity of candidate human addiction-associated genetic enhancers in the striatum, cortex, hippocampus, and amygdala of mice using in vivo massively parallel...
- The National Institute on Drug Abuse awarded Yale University $336,250 on April 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to develop a behavioral foundation model that transforms qualitative epidemiological survey responses into quantitative representations of substance use behaviors. The project harmonizes data from the National Epidemiologic Survey on Alcohol and Related Conditions III (NESARC-III), National Survey on Drug Use and Health (NSDUH), and UK Biobank...
- The National Institute on Drug Abuse awarded the Lieber Institute Inc. $1.855 million on March 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to develop three-dimensional cellular resolution spatio-molecular maps of the human nucleus accumbens across its anterior-posterior axis. The nucleus accumbens is a key node in the brain's reward circuitry, and perturbations in reward signaling are implicated in substance use disorders. The project extends prior spatial...
- The National Institute on Drug Abuse awarded The Trustees of Princeton University $473,543 on September 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to develop theoretical frameworks and computational methods for identifying mechanisms of cognitive computations from neural recordings and behavioral data. The award funds three research aims: formulating mathematical theory relating the dimensionality of neural population dynamics to single-cell selectivity patterns...
- The National Institute on Drug Abuse awarded Boston Children's Hospital $800,131 on May 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to investigate the functions and mechanisms of a molecularly defined prefrontal cortex neuron subtype in drug addiction. The research focuses on identifying and characterizing POU3F1-expressing layer 5 neurons in the prefrontal cortex and their role in regulating cocaine-seeking behavior. The work employs single-cell RNA sequencing...
- The National Institute on Drug Abuse awarded The Washington University $1,155,062 on March 15, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to generate multiomics data characterizing cellular mechanisms underlying fentanyl-induced respiratory depression in opioid overdose decedents. The award funds single-nucleus RNA-seq and ATAC-seq (snRNAseq and snATACseq) paired multiomics analysis of brainstem respiratory control regions—the prebotzinger complex and ventral...
- The National Institute on Drug Abuse awarded a cooperative agreement to Massachusetts General Hospital totaling $1.352 million on July 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279). Massachusetts General Hospital will develop an inexpensive, wearable functional near-infrared spectroscopy (fNIRS) device and integrated software to detect and assess cerebral biomarkers of drug intoxication in real-world settings. The device, designated iFlexNIRS, will feature eight...
- The National Institute on Drug Abuse awarded Biosyft Inc. $301,390 under the Drug Use and Addiction Research Programs (CFDA 93.279) on July 1, 2026, to develop and validate an AI-driven behavioral analysis platform for detecting addiction-like reward signatures in rodent models. Biosyft has built a multi-view chamber system with optimized computer vision models that tracks 29 points across rodents, compared to industry-standard approaches that rely on basic movement tracking or subjective...